Diffuse Large B-Cell Lymphoma Drug Pipeline: 145 Assets by Phase

How many diffuse large B-cell lymphoma drugs are in each phase of development?

Douglas Insights counts 23 diffuse large B-cell lymphoma candidates in Phase III, 16% of the 145 assets in development; Phase II holds 39 and Phase I holds 83.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each diffuse large B-cell lymphoma asset appears in exactly one row. The 432 trials still recruiting or running carry 49% of the 883 registered trials in scope.

Which approved diffuse large B-cell lymphoma medicines are still in trials?

1 medicines already on the market are still being tested in diffuse large B-cell lymphoma Phase IV trials; Rituximab has the most, with 222 registered trials.

Post-approval diffuse large B-cell lymphoma trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many diffuse large B-cell lymphoma trials are recruiting patients now?

231 diffuse large B-cell lymphoma trials are recruiting patients and 73 more have not started recruiting yet, out of 883 interventional trials in scope; together they make up 34% of the trial base.

Terminated, suspended and withdrawn diffuse large B-cell lymphoma trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the diffuse large B-cell lymphoma pipeline?

Genmab leads the diffuse large B-cell lymphoma pipeline with 8 candidates; the top 5 sponsors hold 19% of the 145 assets, and 91 sponsors run at least one.

Industry sponsors lead 317 of the 883 diffuse large B-cell lymphoma trials (36%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the diffuse large B-cell lymphoma pipeline?

Mechanism and drug-type classification for the 145 diffuse large B-cell lymphoma candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What diffuse large B-cell lymphoma trial readouts are coming next?

31 diffuse large B-cell lymphoma candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many diffuse large B-cell lymphoma readouts fall in each quarter?

38 diffuse large B-cell lymphoma candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 14, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most diffuse large B-cell lymphoma trials?

United States hosts the most diffuse large B-cell lymphoma trials, with sites in 488 of the 883 studies (55%); trials in scope run in 64 countries in all.

A multinational diffuse large B-cell lymphoma trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are diffuse large B-cell lymphoma drugs being tested?

488 of the 883 diffuse large B-cell lymphoma trials (55%) have a site in the United States, 216 (24%) in Europe and 239 (27%) in China; 98 of the 145 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational diffuse large B-cell lymphoma trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the diffuse large B-cell lymphoma pipeline since the last update?

Since 3 Oct 2026, the diffuse large B-cell lymphoma pipeline count moved by +7 assets to 145, Phase III moved by +2 and the trial base by 0.

How does Douglas Insights count the diffuse large B-cell lymphoma pipeline?

Douglas Insights read 883 interventional trials registered on ClinicalTrials.gov for the conditions "lymphoma, large b-cell, diffuse", "diffuse large b-cell lymphoma" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 145 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the diffuse large B-cell lymphoma pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage